CDH1 and gastric cancer: Administration of Wnt/β-catenin pathway agonist can promote the proliferation and migration of gastric cancer cells, reduce the levels of N-cadherin, Vimentin, and β-catenin proteins, and increase the levels of E-cadherin proteins.